ALZN
Alzamend Neuro Inc

5,875
Mkt Cap
$6.78M
Volume
33,461.00
52W High
$12.06
52W Low
$1.88
PE Ratio
-0.25
ALZN Fundamentals
Price
$2.23
Prev Close
$2.16
Open
$2.21
50D MA
$2.32
Beta
0.84
Avg. Volume
109,039.79
EPS (Annual)
-$11.32
P/B
1.27
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
Embecta's Q4 earnings loom as product momentum, global trends and recent strategic gains set the stage for potential top-line support.
Zacks·21d ago
News Placeholder
More News
News Placeholder
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 'Lithium in Brain' Study Conducted at Massachusetts General Hospital Alzamend Neuro Announces Completion of...
PR Newswire·22d ago
News Placeholder
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.read more...
Benzinga·22d ago
News Placeholder
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.
Stocktwits·7mo ago
News Placeholder
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·10mo ago
News Placeholder
Alzamend Neuro to Present at the Sequire Investor Summit
Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimers disease (Alzheimers), bipolar disorder...
Business Wire·11mo ago

Latest ALZN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.